Human Vaccines and Immunotherapeutics, 2021 To date, there is no consensus regarding palivizumab prophylaxis for respiratory syncytial virus infection. The purpose of this study is to assess the effectiveness of palivizumab prophylaxis to prevent respiratory syncytial virus-related infection ...
Natividad Viguria +2 more
exaly +2 more sources
Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months [PDF]
ChildrenBackground: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTI) in infants and young children, with significant morbidity, hospitalizations, and healthcare costs.
Andreea Văduva +4 more
doaj +2 more sources
Drug, Healthcare and Patient Safety, 2023 Shaun O’Hagan,1,2 Niamh Galway,3 Michael D Shields,3,4 Peter Mallett,1,4 Helen E Groves1,2 1Paediatric Infectious Diseases, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland; 2Wellcome-Wolfson Institute for Experimental Medicine, Queen ...
Michael D Shields
exaly +2 more sources
Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study [PDF]
Epidemiology and HealthOBJECTIVES Since October 2016, Korea has implemented a national reimbursement program for palivizumab aimed at moderate-to-late preterm (MLPT) infants born between 32 0/7 weels and 35 6/7 weeks of gestation during the respiratory syncytial virus (RSV ...
Seungyeon Kim +3 more
doaj +2 more sources
Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen. [PDF]
PLoS ONE, 2017 Monthly injections of palivizumab during the respiratory syncytial virus (RSV) season in at-risk infants reduces RSV-associated hospitalizations. However, the additive effect of naturally acquired immunity remains unclear. The objective of this study was
Jennifer Claydon +9 more
doaj +1 more source
Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
Viruses, 2023 (1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been ...
Hasindu S. Edirisinghe +10 more
doaj +1 more source
Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. [PDF]
PLoS ONE, 2015 To evaluate the safety and tolerability of palivizumab for RSV prophylaxis in high-risk children in everyday practice.High-risk children prophylaxed against RSV infection were recruited into a prospective, observational, Canadian RSV Evaluation Study of ...
Jinghan Jenny Chen +6 more
doaj +1 more source
BMC Pediatrics, 2021 Background The prophylactic use of anti-respiratory syncytial virus (RSV) antibody (palivizumab) for severe RSV infection is not approved in Japan in specified groups of infants with neuromuscular diseases or other rare diseases associated with reduced ...
Masaaki Mori +8 more
doaj +1 more source
Foods, 2020 Orally delivered antibodies may be useful for the prevention of enteric pathogen infection, but to be effective they need to survive intact across digestion through the gastrointestinal tract.
Bum Jin Kim +4 more
doaj +1 more source
Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
BMJ Paediatrics Open, 2021 In Italy, reimbursement restrictions regarding palivizumab prophylaxis approved in 2016 have been revoked in 2017, restoring use in infants with Gestational Age (GA) >29 weeks.
Marina Davoli +4 more
doaj +1 more source